Bremelanotide Benefits: What the Evidence Actually Supports

Bremelanotide at a glance:

• Drug class: Melanocortin receptor agonist
• Manufacturer: Palatin Technologies / AMAG Pharmaceuticals
• FDA approved: 2019
• Route: subcutaneous injection autoinjector
• Typical frequency: as needed before sexual activity
• Half-life: approximately 2.7 hours
• Cash price (US): $300-$1,000/month

Bremelanotide's benefits split into two categories: what's documented in trials, and what users report anecdotally. Both are interesting; only the first should drive treatment decisions.

Primary Benefit

Statistically significant improvement in HSDD desire and distress measures vs placebo.

That headline outcome is what most labels and trials are designed around. For Bremelanotide: RECONNECT (Kingsberg 2019, Obstet Gynecol).

Approved Indications

Bremelanotide is FDA-approved for: hypoactive sexual desire disorder (HSDD) in premenopausal women.

Within those indications, the benefit is documented and reproducible. Outside them, evidence is weaker and the case for use depends on individual judgment.

Secondary and Pleiotropic Effects

Many drugs in this class have effects beyond their headline indication:

• Compound-specific secondary effects characterized in trials
• Subset of users report benefits beyond the labeled indication

Off-Label Considerations

Off-label use of Bremelanotide is variable. The case for off-label use is strongest when the underlying mechanism plausibly applies and weakest when it relies on extrapolation from related compounds.

Off-label use is legal but typically not insurance-covered, and the prescriber takes on responsibility for the decision.

What Bremelanotide Doesn't Do

A useful counterpoint to "benefits" is what's not supported by evidence:

• Provide a permanent fix that persists after stopping
• Replace lifestyle interventions (it makes them easier; it doesn't substitute for them)
• Produce effects that exceed what the underlying mechanism supports

Cost-Benefit Reasoning

Benefits are easier to evaluate when paired with cost. Bremelanotide costs $300-$1,000/month, and the benefit needs to be weighed against that price tag and the side-effect burden documented elsewhere.

For most users, the benefit/cost calculation is positive when the medication is covered or accessible at a reasonable cash price; it shifts when neither is true.

Bottom Line

Bremelanotide's benefits are real and reproducible within its labeled indication. Outside that, the case weakens fast.

Frequently Asked Questions

Related Reading

• What Is Bremelanotide? Everything You Should Know Before Starting
• Bremelanotide Side Effects: 7 Things to Watch For (and How to Manage Them)
• Bremelanotide Results: What the Real Numbers Show in 2026
• Why Bremelanotide Costs So Much (and 5 Ways to Pay Less)
• hCG: The Complete 2026 Guide (Mechanism, Dosing, Cost)
• What Is Oxytocin? Everything You Should Know Before Starting

Sources

• Kingsberg SA et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder. Obstet Gynecol 2019;134:899.
• Skorupskaite K et al. Kisspeptin and Reproduction in Humans. Hum Reprod Update 2014;20:485.

This page summarizes published evidence and is not medical advice.